United Cost of Revenue vs Total Assets Analysis
UTHR Stock | USD 229.72 13.55 5.57% |
United Therapeutics financial indicator trend analysis is much more than just breaking down United Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether United Therapeutics is a good investment. Please check the relationship between United Therapeutics Cost Of Revenue and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Cost Of Revenue vs Total Assets
Cost of Revenue vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of United Therapeutics Cost of Revenue account and Total Assets. At this time, the significance of the direction appears to have very strong relationship.
The correlation between United Therapeutics' Cost of Revenue and Total Assets is 0.81. Overlapping area represents the amount of variation of Cost of Revenue that can explain the historical movement of Total Assets in the same time period over historical financial statements of United Therapeutics, assuming nothing else is changed. The correlation between historical values of United Therapeutics' Cost of Revenue and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost of Revenue of United Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Cost of Revenue i.e., United Therapeutics' Cost of Revenue and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Cost Of Revenue
Cost of Revenue is found on United Therapeutics income statement and represents the costs associated with goods and services United Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Assets
Total assets refers to the total amount of United Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in United Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from United Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.As of 03/28/2024, Selling General Administrative is likely to drop to about 207.3 M. In addition to that, Discontinued Operations is likely to drop to 5,600
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.8B | 2.1B | 2.2B | Total Revenue | 1.7B | 1.9B | 2.3B | 2.4B |
United Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Other Current Liab | 39.6M | 319.2M | 301.6M | 339.1M | 71M | 116.3M | |
Total Current Liabilities | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 844.6M | |
Total Stockholder Equity | 2.8B | 3.4B | 4.0B | 4.8B | 6.0B | 6.3B | |
Property Plant And Equipment Net | 738.5M | 731.6M | 780.9M | 861.5M | 1.0B | 1.1B | |
Net Debt | 111.6M | 61.3M | (94.8M) | (161.2M) | (507.7M) | (482.3M) | |
Retained Earnings | 3.3B | 3.8B | 4.3B | 5.0B | 6.0B | 6.3B | |
Accounts Payable | 23.1M | 9.9M | 4.1M | 3.8M | 5.6M | 10.2M | |
Cash | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
Non Current Assets Total | 2.0B | 2.4B | 2.8B | 2.7B | 3.6B | 3.8B | |
Non Currrent Assets Other | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 91.5M | |
Cash And Short Term Investments | 2.3B | 3.0B | 3.6B | 4.2B | 3.0B | 3.1B | |
Net Receivables | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 292.8M | |
Common Stock Shares Outstanding | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 50.7M | |
Liabilities And Stockholders Equity | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Non Current Liabilities Total | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 269.4M | |
Other Current Assets | 133.8M | 88.3M | 100.4M | 219.2M | 166.2M | 174.5M | |
Other Stockholder Equity | (531.3M) | (430.5M) | (333.8M) | (190.8M) | (30.2M) | (28.7M) | |
Total Liab | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | |
Total Current Assets | 1.9B | 2.2B | 2.3B | 3.4B | 3.6B | 3.7B | |
Short Term Investments | 747.5M | 1.1B | 1.0B | 1.9B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 738.5M | 731M | 1.1B | 1.2B | 1.5B | 1.5B | |
Intangible Assets | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 84.5M | |
Other Liab | 67M | 79.4M | 104.8M | 76.8M | 88.3M | 60.5M | |
Other Assets | 293.8M | 1.6B | 370.1M | 413.5M | 475.5M | 284.7M | |
Inventory | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 55.9M | |
Property Plant Equipment | 738.5M | 731.6M | 780.9M | 861.5M | 990.7M | 1.0B | |
Net Tangible Assets | 2.6B | 3.2B | 3.9B | 4.8B | 5.5B | 5.7B | |
Retained Earnings Total Equity | 3.3B | 3.8B | 4.3B | 5.0B | 5.8B | 6.1B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GOOG | Alphabet Class C | |
S | SentinelOne |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.8 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.